{"organizations": [], "uuid": "73987ac0efc03c2b57573ff0b9a61812bae42bae", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-parateks-new-drug-applications-for/brief-parateks-new-drug-applications-for-oral-and-intravenous-omadacycline-accepted-for-priority-review-by-fda-idUSASC09UY2", "country": "US", "domain_rank": 408, "title": "BRIEF-Paratek's New Drug Applications For Oral And Intravenous Omadacycline Accepted For Priority Review By FDA", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-04-04T23:14:00.000+03:00", "replies_count": 0, "uuid": "73987ac0efc03c2b57573ff0b9a61812bae42bae"}, "author": "", "url": "https://www.reuters.com/article/brief-parateks-new-drug-applications-for/brief-parateks-new-drug-applications-for-oral-and-intravenous-omadacycline-accepted-for-priority-review-by-fda-idUSASC09UY2", "ord_in_thread": 0, "title": "BRIEF-Paratek's New Drug Applications For Oral And Intravenous Omadacycline Accepted For Priority Review By FDA", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "fda", "sentiment": "negative"}, {"name": "fda reuters staff", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "pdufa", "sentiment": "none"}, {"name": "paratek pharmaceuticals inc", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "April 4, 2018 / 8:16 PM / in 6 minutes BRIEF-Paratek's New Drug Applications For Oral And Intravenous Omadacycline Accepted For Priority Review By FDA Reuters Staff 1 Min Read \nApril 4 (Reuters) - Paratek Pharmaceuticals Inc: \n* PARATEKâ€™S NEW DRUG APPLICATIONS FOR ORAL AND INTRAVENOUS OMADACYCLINE ACCEPTED FOR PRIORITY REVIEW BY FDA * PDUFA ACTION DATE IN OCTOBER 2018 \n* IN NDA ACCEPTANCE LETTER, FDA STATED THAT NO FILING OR POTENTIAL REVIEW ISSUES WERE IDENTIFIED AT THE TIME Source text for Eikon: Further company coverage:", "external_links": [], "published": "2018-04-04T23:14:00.000+03:00", "crawled": "2018-04-04T23:30:41.008+03:00", "highlightTitle": ""}